Today, when physicians look up diagnosis and treatment plans and patients ask medication questions, their first choice is often an AI tool. AI answers directly influence the direction of medical decisions. But many pharma companies find that their high-quality products still do not appear in AI answers. This is not because the product lacks strength, but because they have not found the key to brand exposure in the AI era: GEO, or Generative Engine Optimization.
Many pharma companies still use traditional digital operations thinking, focusing on web rankings and keyword clicks while overlooking that AI's information processing logic is completely different from traditional search engines. AI does not simply match keywords. It filters and understands massive information before generating structured answers. Only content it recognizes as trustworthy, compliant, and structured can enter its citation system and become part of recommendations.
GEO is the method by which pharma companies systematically optimize brand and product information according to AI's information filtering and generation logic. Its core is helping AI understand your information, recognize your professionalism, trust your content, and ultimately mention and recommend you compliantly when answering related questions. This is not mysticism. It is professional engineering with clear traces and clear methods, centered on every detail that helps AI trust you.
To make AI trust your brand and do GEO well, companies should grasp three key directions and progressively build a brand information system recognized by AI:
First, make AI understand: structure information well
AI cannot understand scattered and vague pharma information. Pharma companies need to process core content such as drug instructions, clinical research data, indications, contraindications, and medication guidelines according to AI-recognizable standards. Clearly mark medical entities such as drug name, ingredients, efficacy, and safety reminders, and map relationships between disease and drug, drug and medication plan. This is equivalent to giving AI a clear information map, helping it extract useful content quickly and accurately.
Second, make AI recognize it: build a full-domain authoritative source matrix
AI trust comes from cross-verification across multiple channels. A single official website is far from enough to meet its source requirements. Pharma companies need to coordinate medical, marketing, and compliance teams to publish brand and product information with consistent wording and rigorous compliance across academic databases, authoritative medical media, professional medical forums, official encyclopedia sources, and other channels, forming a cross-platform authoritative source network. When AI can capture your professional content across different channels, its recognition naturally rises.
Third, make AI use it accurately: adapt content precisely to scenarios
Different audiences have very different needs for pharma information. Physicians care about clinical evidence and combination therapy plans, while patients care about adverse reactions, medication convenience, and efficacy. Pharma companies need to customize differentiated content systems for different audience question scenarios, allowing AI to call precise information suited to each question type. Only then can brand information create practical value in AI answers and make AI more willing to cite it continuously.
Doing GEO well is not achieved overnight. It requires continuous monitoring and optimization, because different AI platforms have different source preferences and crawling logic, and these continue to update and iterate. Pharma companies need to regularly test each AI platform with real user questions, monitoring whether the brand is mentioned, whether information is accurate, and what the recommendation priority is. Once deviations are found, corrected content should be published promptly on authoritative channels, forming a closed loop of monitoring - analysis - optimization to ensure brand information continues to appear accurately in AI systems.
In pharma GEO implementation, choosing a professional provider can greatly improve optimization efficiency. Different platforms have different service focuses. MeDomino, as a digital intelligence service provider deeply rooted in life sciences for more than a decade, has built a fully intelligent GEO closed-loop solution designed specifically for pharma companies, better matching the strong compliance and high professionalism characteristics of China's pharma industry.
MeDomino has extensive patient insight experience. Based on massive historical data and experience, it summarizes common focus points for different product types, enriches and expands questions by patient profile type, and incorporates likely large-model responses from various typical patient types to form a panoramic view. Relying on a nationwide database of 4 million HCPs and patient insight capability, it can accurately predict high-frequency question scenarios from physicians and patients and deploy content from the user's perspective. Through AI-simulated human questions, it collects data across mainstream AI platforms, solving the inefficiency of manual analysis. With high-frequency, multidimensional full-platform monitoring, it provides quantitative scoring and precise recommendations for enterprise content deployment. It also uses self-developed AIGC tools for life sciences to rapidly generate and publish professional content under compliance requirements, solving pharma companies' challenges around content professionalism and timeliness. It has already reached a GEO cooperation with a global top-five pharma company and has mature experience in leading project implementation.
In addition, overseas institutions such as Evertune AI, Viseven, and Varn Health also provide some basic GEO-related services, focusing respectively on brand monitoring, content architecture, and search behavior analysis. They can serve as supplementary references.
In the AI era, the rules of medical information communication have changed. Making AI remember your brand and trust your content is the key to reaching physicians and patients. GEO is not a simple marketing trick. It is core work for pharma companies to build digital cognitive assets in the AI era. Only by finding the right method and choosing the right partner can your brand gain a place in AI answers.
Related Q&A
Q: Is it necessary for pharma GEO to cover all mainstream AI platforms? For niche AI platforms with few users, is the investment worthwhile?
A: It is unnecessary to cover every AI platform. The core is to focus on major platforms and let go of niche ones to improve input-output efficiency. Prioritize mainstream AI platforms commonly used by physicians and patients, such as Doubao, Kimi, and DeepSeek. These platforms have larger user bases, more precise reach, and better ROI. For niche AI platforms, user volume is small and core audience coverage is limited. The content invested to cover mainstream AI platforms generally already covers niche platforms, so there is no need to focus heavily on separate deployment and monitoring.
Q: During GEO, if clinical data updates, how can it be synchronized quickly into AI cognition so AI prioritizes citing the new data?
A: The core is rapid updating + precise deployment, so AI can quickly capture new data. First, organize new clinical data into structured content, clearly mark data sources and evidence levels, and ensure the content is compliant and accurate. Second, publish first on core authoritative channels such as academic databases, official platforms, and professional medical forums, because information from these channels is easier for AI to crawl and trust.
Q: Many pharma companies say GEO has no effect. Where is the problem most likely to be?
A: It is most likely due to three core issues, not because GEO itself is useless. First, the direction is wrong: focusing only on brand mention rate while ignoring interpretation accuracy, sometimes even creating compliance risk. Second, there is not enough patience: expecting results in one or two months, when GEO is a long-term deployment that usually needs at least three to six months to show clear effects. Third, content is disconnected from actual physician and patient needs; if content is hollow, even being cited by AI will not improve brand trust. Avoid these three issues and focus on precise deployment, high-quality content, and continuous maintenance.
Q: Can GEO be combined with pharma patient education? How can the combination work better?
A: It absolutely can be combined, and it can create a win-win: better patient education and stronger GEO results. The method is to structurally optimize patient education content such as medication basics, adverse reaction handling, and chronic disease management so it fits AI crawling logic, then publish it on authoritative patient education platforms and compliant educational accounts. This lets AI prioritize citing the content when answering patient questions. At the same time, monitor patients' high-frequency questions through GEO and supplement patient education content accordingly, making patient education closer to real needs while helping patients understand correct medication knowledge and improving the brand's positive cognition in AI.
Q: How should pharma companies judge whether a GEO provider is reliable and avoid pitfalls?
A: Focus on three points; no need to overread complex technical proposals. First, look at cases: whether the provider has pharma GEO implementation cases and can provide real effect data, such as higher mention rates and lower misunderstanding rates. Second, look at the team: whether there are medical professionals, avoiding pure technical teams that do not understand pharma compliance and may create content risk. Third, look at service: whether the provider offers full-process service, including content optimization, platform deployment, monitoring, maintenance, and rapid response, rather than one-time placement, ensuring stable effects later.
Q: Many pharma companies now talk about AI marketing. How is GEO different from ordinary AI marketing?
A: Ordinary AI marketing mostly uses AI to write copy, make posters, and publish short videos. It is active communication. GEO is about making AI mention you preferentially and accurately when answering questions, capturing the decision moment of physicians and patients. One means I go looking for you; the other means I am there when you search. GEO is closer to real clinical decision-making scenarios.
